Nicosia Luca, Latronico Antuono, Addante Francesca, De Santis Rossella, Bozzini Anna Carla, Montesano Marta, Frassoni Samuele, Bagnardi Vincenzo, Mazzarol Giovanni, Pala Oriana, Lazzeroni Matteo, Lissidini Germana, Mastropasqua Mauro Giuseppe, Cassano Enrico
Department of Breast Radiology, IEO European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Department of Emergency and Organ Transplantation, Section of Anatomic Pathology, School of Medicine, University "Aldo Moro", 70124 Bari, Italy.
Diagnostics (Basel). 2021 Jun 19;11(6):1120. doi: 10.3390/diagnostics11061120.
(1) Background: to evaluate which factors can reduce the upgrade rate of atypical ductal hyperplasia (ADH) to in situ or invasive carcinoma in patients who underwent vacuum-assisted breast biopsy (VABB) and subsequent surgical excision. (2) Methods: 2955 VABBs were reviewed; 141 patients with a diagnosis of ADH were selected for subsequent surgical excision. The association between patients' characteristics and the upgrade rate to breast cancer was evaluated in both univariate and multivariate analyses. (3) Results: the upgrade rates to ductal carcinoma in situ (DCIS) and invasive carcinoma (IC) were, respectively, 29.1% and 7.8%. The pooled upgrade rate to DCIS or IC was statistically lower at univariate analysis, considering the following parameters: complete removal of the lesion (-value < 0.001); BIRADS ≤ 4a (-value < 0.001); size of the lesion ≤15 mm (-value: 0.002); age of the patients <50 years (-value: 0.035). (4) Conclusions: the overall upgrade rate of ADH to DCIS or IC is high and, as already known, surgery should be recommended. However, ADH cases should always be discussed in multidisciplinary meetings: some parameters appear to be related to a lower upgrade rate. Patients presenting these parameters could be strictly followed up to avoid overtreatment.
(1) 背景:评估在接受真空辅助乳腺活检(VABB)及后续手术切除的患者中,哪些因素可降低非典型导管增生(ADH)进展为原位癌或浸润癌的升级率。(2) 方法:回顾了2955例VABB病例;选择141例诊断为ADH的患者进行后续手术切除。在单因素和多因素分析中评估患者特征与乳腺癌升级率之间的关联。(3) 结果:原位导管癌(DCIS)和浸润癌(IC)的升级率分别为29.1%和7.8%。在单因素分析中,考虑以下参数时,DCIS或IC的合并升级率在统计学上较低:病变完全切除(P值<0.001);乳腺影像报告和数据系统(BIRADS)≤4a(P值<0.001);病变大小≤15mm(P值:0.002);患者年龄<50岁(P值:0.035)。(4) 结论:ADH进展为DCIS或IC的总体升级率较高,如已知的那样,应推荐手术。然而,ADH病例应始终在多学科会议上进行讨论:一些参数似乎与较低的升级率相关。具有这些参数的患者可进行严格随访以避免过度治疗。